A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes

Exclusion Criteria

• •Are using prandial, self-mixed, or premixed insulin. Participants using prandial insulin may be switched to everyday (qd) glargine if investigator judges that the participant will still meet fasting glucose requirements for randomization.
• •Are using insulin pump therapy.
• •Have excessive insulin resistance: Defined as \>1.0 unit/kg/day as baseline treatment.
• •If being treated with sulfonylureas (SUs) before screening, then must have SUs washed out between screening and randomization.
• •Use any of these concomitant medications: morphine, codeine, antidiuretics, glucagon-like peptide-1 (GLP-1) receptor agonists (for example, exenatide, exenatide once weekly, lixisenatide or liraglutide), or pramlintide, used concurrently or within 90 days before screening.
• •Have hypoglycemia unawareness, defined as confirmed by laboratory test results or by historical episodes of hypoglycemia \<54 mg/dL (3.0 mmol/L) without symptoms.
• •Have fasting hypertriglyceridemia \>400 mg/dL (\>4.5 mmol/L) at screening, as determined by the local laboratory.
• •Have had any episode of severe hypoglycemia (defined by requiring assistance due to neurologically disabling hypoglycemia) within 6 months before entry into the study.
• •Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months.
• •Have had a previous clinically significant episode of ketoacidosis as determined by the investigator (ketone bodies at fasting and without acidosis is acceptable) in the past 6 months.
• •Have history of renal transplantation, are currently receiving renal dialysis, or have estimated Glomerular Filtration Rate (eGFR) \<60 milliliters/minute.
• •Have obvious clinical signs or symptoms of liver disease (excluding nonalcoholic fatty liver disease), acute or chronic hepatitis, nonalcoholic steatohepatitis, or elevated liver enzyme measurements.
• •Have active or untreated malignancy, have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years, or are at increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator.